The use of nucleic acid amplification techniques to increase the viral safety of blood

Clinical Laboratory

Volumn 48, Issue 3-4, 2002, Pages 155-160

  Thomas, Isabelle ^a   Mathys, Esther ^a   Gerard, Carine ^a  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

Blood safety; Blood borne viruses; NAT; PCR

Indexed keywords

VIRUS ANTIBODY;

ARTICLE; BLOOD DONOR; CONTAMINATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PREVALENCE; RISK; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; TECHNOLOGY; VIRUS DETECTION; VIRUS GENOME; VIRUS INFECTION; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS REPLICATION;

BELGIUM; BLOOD BANKS; BLOOD TRANSFUSION; DNA, VIRAL; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; VIRUS DISEASES;

EID: 0036203267     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Failure of 2nd- and 3rd- generation HCV ELISA and RIBA to detect HCV polymerase chain reaction-positive donations
2. Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles
3. Transfusion-transmissible infections
4. Transmission of hepatitis C virus by anti-HCV-negative blood transfusion. Case report
5. The risk of transfusion-transmitted viral infections
6. Considerations of pool size in the manufacture of plasma derivatives
7. Safety issues for plasma derivatives and benefit from NAT testing
8. Infectious risk of plasma donations: Relationship to safety of intravenous immune globulins
9. Hepatitis C transmission associated with intravenous immunoglobulins
10. Committee report. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases: Report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors
11. Risk-benefit analysis of nucleic acid testing: The French experience
12. Results of viral marker screening of unpaid blood donations and probability of window period donations in 1997
13. Reliability of polymerase chain reaction for detection of hepatitis C virus
14. International collaborative study on the second EUROHEP HCV-RNA reference panel
15. Validation and standardisation of nucleic acid amplification technology (NAT) assays for the detection of viral contamination of blood and blood products
16. Guidelines for validation of nucleic acid amplification technology (NAT) for the detection of hepatitis C virus (HCV) RNA in plasma pools. PA/PH/OMCL(98)22,DEF
17. Anforderungen an Validierung und Routinebetrieb der HCV-RNA im Blutspendewesen
18. Two years of experience with PCR screening of individual blood donations
19. Large-scale HCV RNA screening in first-time blood donors: The first step towards genomic screening of blood donations
20. NAT and viral safety in blood transfusion
21. PCR detects HCV RNA in a plasma pool contaminated by a single preseroconversion donation of genotype 5a
22. Hepatitis B virus DNA in the serum of Sardinian blood donors negative for the hepatitis B surface antigen
23. Viral genetic variation: Hepatitis B virus as a clinical example
24. Virology of the hepatitis A epidemic in Italy
25. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactive viruses
26. Human parvovirus infection in pregnancy and hydrops fetalis
27. Immune response to B19 parvovirus and an antibody defect in persistent viral infection
28. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates
29. Life-threatening human parvovirus B19 infection in immunocompetent haemophilia
30. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma
31. Molecular cloning and disease association of hepatitis G virus: A transfusion-transmissible agent
32. Sequence and genomic organization of GBV-C: A novel member of the flaviviridae associated with human non-A-E hepatitis
33. Hepatitis G virus biology, epidemiology, and clinical manifestations: Implications for blood safety
34. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology
35. Application of nucleic acid amplification techniques for blood donation screening
36. Testing of individual blood donations for HCV RNA reduces the residual risk of transfusion-transmitted HCV infection
37. Experiences in HCV-NAT screening prior to releasing cellular components by the German Red Cross Blood Transfusion Service of Baden-Wurttemberg
38. NAT of the United States and Canadian blood supply
39. Validation of the NucliSens Extractor in combination with the hepatitis C virus Cobas Amplicor 2.0 assay in four laboratories in the Netherlands utilizing nucleic acid amplification technology for blood screening
40. A model of the health and economic impact of posttransfusion hepatitis C: Application to cost-effectiveness analysis of further expansion of HCV screening protocols